The 40 kinase substrate signature obtained between BRAF wild-type and BRAF(V600E) melanoma tumor samples after ex-vivo treatment with vemurafenib was similar to the signature obtained with in-vitro vemurafenib treatment between BRAF wild-type and vemurafenib-resistant BRAF(V600E) cells (Table 2). The gene discussed is BRAF; the disease is neoplasm.